Compare IPHA & LCNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IPHA | LCNB |
|---|---|---|
| Founded | 1999 | 1877 |
| Country | France | United States |
| Employees | 163 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.5M | 223.1M |
| IPO Year | N/A | 1999 |
| Metric | IPHA | LCNB |
|---|---|---|
| Price | $1.76 | $16.91 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.75 | N/A |
| AVG Volume (30 Days) | ★ 134.2K | 15.7K |
| Earning Date | 03-26-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 5.43% |
| EPS Growth | N/A | ★ 68.04 |
| EPS | N/A | ★ 0.31 |
| Revenue | N/A | ★ $6,445,000.00 |
| Revenue This Year | $180.36 | $8.50 |
| Revenue Next Year | N/A | $3.66 |
| P/E Ratio | ★ N/A | $54.32 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.18 | $13.75 |
| 52 Week High | $2.63 | $17.89 |
| Indicator | IPHA | LCNB |
|---|---|---|
| Relative Strength Index (RSI) | 54.22 | 63.69 |
| Support Level | $1.72 | $15.30 |
| Resistance Level | $2.32 | $17.36 |
| Average True Range (ATR) | 0.20 | 0.42 |
| MACD | -0.01 | 0.12 |
| Stochastic Oscillator | 40.00 | 92.22 |
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections, and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.